ZIVOW
Income statement / Annual
Last year (2024), ZIVO Bioscience, Inc.'s total revenue was $157,220.00,
an increase of 468.61% from the previous year.
In 2024, ZIVO Bioscience, Inc.'s net income was -$13.38 M.
See ZIVO Bioscience, Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
Operating Revenue |
$157,220.00 |
$27,650.00 |
$0.00 |
$0.00 |
$20,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Cost of Revenue |
$108,268.00
|
$16,040.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Gross Profit |
$48,952.00
|
$11,610.00
|
$0.00
|
$0.00
|
$20,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Gross Profit Ratio |
0.31
|
0.42
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
Research and Development Expenses |
$3.13 M
|
$1.38 M
|
$2.24 M
|
$2.12 M
|
$3.75 M
|
$2.31 M
|
$2.81 M
|
$2.38 M
|
$788,971.00
|
$1.03 M
|
General & Administrative Expenses |
$10.28 M
|
$5.90 M
|
$6.49 M
|
$6.93 M
|
$4.82 M
|
$6.05 M
|
$3.32 M
|
$3.95 M
|
$2.70 M
|
$2.02 M
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$10.28 M
|
$5.90 M
|
$6.49 M
|
$6.93 M
|
$4.82 M
|
$6.05 M
|
$3.32 M
|
$3.95 M
|
$2.70 M
|
$2.02 M
|
Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Operating Expenses |
$13.41 M
|
$7.27 M
|
$8.73 M
|
$9.05 M
|
$8.58 M
|
$8.35 M
|
$6.13 M
|
$6.33 M
|
$3.49 M
|
$3.06 M
|
Cost And Expenses |
$13.52 M
|
$7.29 M
|
$8.73 M
|
$9.05 M
|
$8.58 M
|
$8.35 M
|
$6.13 M
|
$6.33 M
|
$3.49 M
|
$3.06 M
|
Interest Income |
$0.00
|
$0.00
|
$13,319.00
|
$233,282.00
|
$550,054.00
|
$3.16 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Interest Expense |
$22,939.00
|
$514,172.00
|
$13,319.00
|
$233,281.00
|
$550,054.00
|
$3.16 M
|
$8.10 M
|
$1.83 M
|
$986,188.00
|
$720,711.00
|
Depreciation & Amortization |
$0.00
|
$0.00
|
$4.00
|
-$407,491.00
|
$8.56 M
|
$8.35 M
|
$18,750.00
|
$18,750.00
|
$25,000.00
|
$25,000.00
|
EBITDA |
-$13.36 M |
-$7.26 M |
-$8.73 M |
-$9.05 M |
-$550,054.00 |
-$8.35 M |
-$6.13 M |
-$6.33 M |
-$3.49 M |
-$3.06 M |
EBITDA Ratio |
-84.99
|
-262.68
|
0
|
0
|
-427.78
|
0
|
0
|
0
|
0
|
0
|
Operating Income Ratio |
-84.99
|
-262.68
|
0
|
0
|
-427.78
|
0
|
0
|
0
|
0
|
0
|
Total Other Income/Expenses Net |
-$22,939.00
|
-$514,172.00
|
-$13,319.00
|
-$110,762.00
|
-$550,054.00
|
-$3.16 M
|
-$8.50 M
|
-$3.71 M
|
-$2.57 M
|
-$2.73 M
|
Income Before Tax |
-$13.38 M
|
-$7.78 M
|
-$8.75 M
|
-$9.16 M
|
-$9.11 M
|
-$11.51 M
|
-$14.64 M
|
-$10.04 M
|
-$6.06 M
|
-$5.79 M
|
Income Before Tax Ratio |
-85.13
|
-281.27
|
0
|
0
|
-455.29
|
0
|
0
|
0
|
0
|
0
|
Income Tax Expense |
$0.00
|
$0.00
|
-$4.00
|
$233,281.00
|
$550,054.00
|
$3.16 M
|
$407,487.00
|
$1.66 M
|
$1.40 M
|
$1.83 M
|
Net Income |
-$13.38 M
|
-$7.78 M
|
-$8.75 M
|
-$9.40 M
|
-$9.66 M
|
-$14.67 M
|
-$14.64 M
|
-$10.04 M
|
-$6.06 M
|
-$5.79 M
|
Net Income Ratio |
-85.13
|
-281.27
|
0
|
0
|
-482.79
|
0
|
0
|
0
|
0
|
0
|
EPS |
-3.92 |
-4.6 |
-5.58 |
-7.4 |
-11.41 |
-25.47 |
-44.84 |
-34.6 |
-21.73 |
-21.22 |
EPS Diluted |
-3.92 |
-4.6 |
-5.57 |
-7.39 |
-11.41 |
-25.47 |
-44.84 |
-34.6 |
-21.73 |
-21.22 |
Weighted Average Shares Out |
$3.41 M
|
$1.69 M
|
$1.57 M
|
$1.27 M
|
$846,212.00
|
$575,826.00
|
$326,414.00
|
$290,090.00
|
$278,842.00
|
$272,804.00
|
Weighted Average Shares Out Diluted |
$3.41 M
|
$1.69 M
|
$1.57 M
|
$1.27 M
|
$846,212.00
|
$575,826.00
|
$326,414.00
|
$290,090.00
|
$278,842.00
|
$272,804.00
|
Link |
|
|
|
|
|
|
|
|
|
|